|Articles|September 27, 2019

Rwanda Is On Track to Control HIV Epidemic, According to Survey Results

According to results from the Rwanda Population-based HIV Impact Assessment (RPHIA), 76% of all adults living with HIV in Rwanda have achieved viral load suppression.

The US Centers for Disease Control and Prevention (CDC) has announced that Rwanda has made tremendous progress towards controlling the HIV epidemic.

According to results from the Rwanda Population-based HIV Impact Assessment (RPHIA), 76% of all adults living with HIV in Rwanda have achieved viral load suppression. This figure surpasses the Joint United Nations Program on HIV/AIDS (UNAIDS) target of 73% by 2020.

Nationally, Rwanda has also made significant progress towards the 90-90-90 UNAIDS targets. When combining self-reported and laboratory data, 84% of adults living in Rwanda were aware of their status based on self-reporting or the detection of antiretrovirals (ART) in participants’ blood samples. Of the adults who knew their HIV status, 97.5% were on ART, based on self-reporting or ART detection in the blood. Of the adults using ART, 90.1% were found to have viral load suppression.

The preliminary results of the survey are reflective of the effort that Rwanda has put into establishing national HIV programs and policies with a focus on reducing new infections and providing linkage to care for people living with HIV.

“Rwanda has already reached and exceeded the global 2020 HIV targets, and this is a testament to the Government of Rwanda’s commitment to confronting its HIV epidemic,” noted Wafaa El-Sadr, MD, MPH, MPA, director of ICAP in the CDC’s statement. “The RPHIA results illustrate the importance of population-based surveys in measuring the progress and impact of national HIV programs and policies.”

The RPHIA survey was disseminated to more than 11,00 households from October 2018 through March 2019. The survey reached more than 30,000 adults aged 15-64 years, and more than 9000 adolescents aged 10-14 years.

When participants returned the survey, they were given access to home-based HIV testing and counseling and linkage to care for those who tested positive for HIV.

The preliminary results include information on the percentage of people living with HIV, the number of new HIV infections occurring each year, and the percentage of people with viral level suppression described by age, sex, and geographic variation.

Survey results also report that approximately 210,200 adults between the ages of 15-64 years in Rwanda were living with HIV (prevalence 3.0%). The prevalence was higher in women (3.7%) than men (2.2%) and 1.9 times higher in urban areas compared with rural areas.

Annually, the incidence of HIV was 0.08%, equating to approximately 5400 new cases per year in Rwanda. Among all adults living with HIV, 76% had suppressed viral loads. Women had higher rates of viral suppression (79.1%) than men (70.5%).

The full results of RPHIA will be released on October 22, 2019. According to the CDC, these results will dictate the future direction of Rwanda’s efforts to control the HIV epidemic and close existing gaps.


Related to this article

Ebola Outbreak Tops 10,000 Cases as CDC Cites Spread to Kenya, Nigeria
The CDC reports the Bundibugyo virus outbreak in the Democratic Republic of the Congo (DRC) is now the second-largest Ebola outbreak on record. As of October 28, the agency counted 10,305 total confirmed cases and 4,996 total confirmed deaths. The overall risk to the American public and travelers remains low, and no cases tied to this outbreak have been confirmed in the US.
Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.